Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union. Shares were recently 12% lower at 5,852 yen, or about $38.06, Monday morning after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback